A novel chemotherapeutic arene ruthenium(II) drug Rawq01 altered the effect of microRNA-21 on PTEN/AKT signaling pathway in esophageal cancer cells

Anticancer Research

Volumn 33, Issue 12, 2013, Pages 5407-5414

  Weng, Wenhao ^a   Wu, Qiong ^a   Yu, Yongchun ^a   Mei, Wenjie ^b   Wang, Xinghe ^c  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Pharmaceutical University   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

AKT; Esophageal squamous cell carcinoma; MicroRNA 21; PTEN; Ruthenlium

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; MICRORNA 21; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAWQ 01; RAWQ01; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS ASSAY; ARTICLE; CONTROLLED STUDY; ESOPHAGUS CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84891448720     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Zhao P, Dai M, Chen W and Li N: Cancer trends in China. Jpn J Clin Oncol 40: 281-285, 2010.
2. Yang CS: Research on esophageal cancer in China. Cancer Res 40: 2633-2644, 1980.
3. Xing D, Tan W, and Lin D: Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population. Oncol Rep 10: 1615-1623, 2003
4. Sriskandakumar T, Petzold H, Bruijnincx PC, Habtemariam A, Sadler PJ and Kennepohl P: Influence of oxygenation on the reactivity of ruthenium-thiolato bonds in arene anticancer complexes: insights from XAS and DFT.J Am Chem Soc 131: 13355-13361, 2009.
5. Suss-Fink G: Arene ruthenium complexes as anticancer agents.Dalton Trans 39: 1673-1688, 2010.
6. Smith GS and Therrien B: Targeted and multifunctional arene ruthenium chemotherapeutics.Dalton Trans 40: 10793-10800, 2011.
7. Dougan SJ, Habtemariam A, McHale SE, Parsons S and Sadler PJ: Catalytic organometallic anticancer complexes. Proc Natl Acad Sci USA 105: 11628-11633, 2008.
8. Ohkuma T, Utsumi N, Tsutsumi K, Murata K, Sandoval C and Noyori R: The hydrogenation/transfer hydrogenation network: Asymmetric hydrogenation of ketones with chiral eta6-arene/N-tosylethylenediamine-ruthenium(II) catalysts. J Am Chem Soc 128: 8724-8725, 2006.
9. Hu W, Luo Q, Ma X, Wu K, Liu J, Chen Y, Xiong S, Wang J, Sadler PJ and Wang F: Arene control over thiolate to sulfinate oxidation in albumin by organometallic ruthenium anticancer complexes.Chemistry 15: 6586-6594, 2009.
10. Liu HK and Sadler PJ: Metal complexes as DNA intercalators. Acc Chem Res 44: 349-359, 2011.
11. Aird RE, Cummings J, Ritchie AA, Muir M, Morris RE, Chen H, Sadler PJ and Jodrell DI: In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.Br J Cancer 86: 1652- 1657, 2002.
12. Morris RE, Aird RE, Murdoch Pdel S, Chen H, Cummings J, Hughes ND, Parsons S, Parkin A, Boyd G, Jodrell DI and Sadler PJ: Inhibition of cancer cell growth by ruthenium(II) arene complexes. J Med Chem 44: 3616-3621, 2001.
13. Claire S. Allardyce, Paul J. Dyson, David J, Ellis and Sarah L: Heath: [Ru(η6-p-cymene)Cl2(pta)] (pta=1,3,5-triaza-7-phosphatricyclo- [3.3.1.1]decane): a water soluble compound that exhibits pH- dependent DNA binding providing selectivity for diseased cells. Chem. Commun 15: 1396-1397, 2001.
14. Dyson and Paul J: Systematic Design of a Targeted Organometallic Antitumour Drug in Pre-clinical Development. CHIMIA Inte J Chemi 61: 698-703, 2007.
15. Martínez A, Rajapakse CS, Sánchez-Delgado RA, Varela-Ramirez A, Lema C and Aguilera RJ: Arene-Ru(II)-chloroquine complexes interact with DNA, induce apoptosis on human lymphoid cell lines and display low toxicity to normal mammalian cells. J Inorg Biochem 104: 967-977, 2010.
16. Scolaro C, Bergamo A, Brescacin L, Delfino R, Cocchietto M, Laurenczy G, Geldbach TJ, Sava G and Dyson PJ: In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J Med Chem 48: 4161-4171, 2005.
17. Renfrew AK, Phillips AD, Tapavicza E, Scopelliti R, Rothlisberger U and Dyson PJ: Tuning the Efficacy of Ruthenium(II)-Arene (RAPTA) Antitumor Compounds with Fluorinated Arene Ligands. Organometallics 28: 5061-5071, 2009.
18. Chatterjee S, Kundu S, Bhattacharyya A, Hartinger CG and Dyson PJ: The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways.J Biol Inorg Chem 13: 1149-1155, 2008.
19. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and Gonzalez-Baron M: PI3K/Akt signalling pathway and cancer. Cancer, Treat Rev 30: 193-204, 2004.
20. Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.
21. Bozulic L and Hemmings BA: PIKKing on PKB: Regulation of PKB activity by phosphorylation. Curr Opin Cell Biol 21: 256-261, 2009.
22. Vivanco I and Sawyers CL: The phosphatidylinositol 3- Kinase/AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
23. Fry MJ: Phosphoinositide 3-kinase signalling in breast cancer: How big a role might it play? Breast Cancer Res 3: 304-312, 2001.
24. Lin X, Bohle AS, Dohrmann P, Leuschner I, Schulz A and Kremer B: Overexpression of phosphatidylinositol 3-kinase in human lung cancer. Langenbecks Arch Surg 386: 293-301, 2001.
25. Krasilnikov M, Adler V, Fuchs SY, Dong Z, Haimovitz-Friedman A and Herlyn M: Contribution of phosphatidylinositol 3-Kinase to radiation resistance in human melanoma cells. Mol Carcinog 24: 64-69, 1999.
26. Martinez-Lorenzo MJ, Anel A, Monleon I, Sierra JJ, Pineiro A and Naval J: Tyrosine phosphorylation of the p85 subunit of phosphatidylinositol 3-kinase correlates with high proliferation rates in sublines derived from the Jurkat leukemia. Int J Biochem Cell Biol 32: 435-445, 2000.
27. Blume-Jensen P and Hunter T: Oncogenic kinase signalling. Nature 411: 355-365, 2001.
28. Lu J, Getz G and Miska EA: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
29. Kent OA and Mendell JT: A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 25: 6188-6196, 2006.
30. Chan JA, Krichevsky AM and Kosik KS: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65: 6029-6033, 2005.
31. Meng F, Henson R and Wehbe JH: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133: 647-658, 2007.
32. Ma WJ, Lv GD and Tuersun A: Role of microRNA-21 and effect on PTEN in Kazakh's esophageal squamous cell carcinoma.Mol Biol Rep 38: 3253-3260, 2011.
33. Zelonka RA and Baird MC: Benzene Complexes of Ruthenium(II).Can J Chemi 50: 3063-3072, 1972.
34. Nesbit CE, Tersak JM and Prochownik EV: MYC oncogenes and human neoplastic disease. Oncogene 18: 3004-3016, 1999.
35. Fan SH, Zhang AG, Ju CC, Gao LH and Wang KZ: A triphenylamine-grafted imidazo[4,5-f][1,10]phenanthroline ruthenium(II) complex: Acid-base and photoelectric properties. Inorg Chem 49: 3752-3763, 2010.
36. Therrien B: Functionalised eta(6)-arene ruthenium complexes. J Coord Chem Rev 253: 493-519, 2009.
37. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using realtime quantitative PCR and the 2(-delta delta C(T)) method. Methods 25: 402-408, 2001.
38. Jiang BH, Zheng JZ, Aoki M and Vogt PK: Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 97: 1749-1753, 2000.
39. Allardyce CS and Dyson PJ: Ruthenium in medicine: Current clinical uses and future prospects. Platinum Metals Rev 45: 62-69, 2001.
40. Paez J and Sellers WR: PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res 115: 145-167, 2003.
41. Blume-Jensen P and Hunter T: Oncogenic kinase signalling. Nature 411: 355-365, 2001.
42. Li L and Ross AH: Why is PTEN an important tumor suppressor? Cell Biochem 102: 1368-1374, 2007.
43. Maehama T: PTEN: Its deregulation and tumorigenesis. Biol Pharm Bull 30: 1624-1627, 2007.
44. Tachibana M, Shibakita M, Ohno S, Kinugasa S, Yoshimura H, Ueda S, Fujii T, Rahman MA, Dhar DK and Nagasue N: Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma. Cancer 94: 1955-1960, 2002.
45. Hu YC, Lam KY, Tang JC and Srivastava G: Mutational analysis of the PTEN/MMAC1 gene in primary oesophageal squamous cell carcinomas.Mol Pathol 52: 353-356, 1999.
46. Chang D, Wang TY, Li HC, Wei JC and Song JX: Prognostic significance of PTEN expression in esophageal squamous cell carcinoma from Linzhou City, a high incidence area of northern China. Dis Esophagus 20: 491-496, 2007.
47. Han M, Liu M, Wang Y, Chen X, Xu J, Sun Y, Zhao L, Qu H, Fan Y and Wu C: Antagonism of miR-21 Reverses Epithelial- Mesenchymal Transition and Cancer Stem Cell Phenotype through AKT/ERK1/2 Inactivation by Targeting PTEN. PLoS One 7: e39520, 2012.
48. Zhang BG, Li JF, Yu BQ, Zhu ZG, Liu BY and Yan M: MicroRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol Rep 27: 1019-1026, 2012.
49. Feng YH, Wu CL, Shiau AL, Lee JC, Chang JG, Lu PJ, Tung CL, Feng LY, Huang WT and Tsao CJ: MicroRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells.Int J Mol Med 9: 920-926, 2012.
50. Akagi I, Miyashita M, Ishibashi O, Mishima T, Kikuchi K, Makino H, Nomura T, Hagiwara N, Uchida E and Takizawa T: Relationship between altered expression levels of MIR21, MIR143, MIR145, and MIR205 and clinicopathologic features of esophageal squamous cell carcinoma. Dis Esophagus 24: 523-530, 2011.
51. Wong ST, Zhang XQ, Zhuang JT, Chan HL, Li CH and Leung GK: MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide- resistant glioblastoma cells. Anticancer Res 32: 2835-2841, 2012.
52. Zhou YA, Zhang T, Zhao JB, Wang XP, Jiang T, Gu ZP, Wang XN and Li XF: The adenovirus-mediated transfer of PTEN inhibits the growth of esophageal cancer cells in vitro and in vivo. Biosci Biotechnol Biochem 74: 736-740, 2010.